Skip to content

Kymera Therapeutics KYMR Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$69.23M-5.6%-$86.98M-22.9%-$82.18M-31.5%-$76.61M-82.1%-$65.58M-35.1%
$2.02M-1.3%$2.03M+2.3%$2.15M+8.2%$2.08M+7.5%$2.05M+40.2%
$16.01M+12.5%$14.45M+4.7%$15.8M+6.0%$15.42M+7.5%$14.23M+18.9%
-$88.84M-12.2%-$66.75M-8.0%-$27.11M+46.0%-$59.88M-39.5%-$79.15M-99.9%
$434K-7.1%$106K-88.7%$181K$695K-85.2%$467K-93.7%
-$142.84M-394%-$394.4M-$235.3M-49.2%$60.02M$48.62M+115%
$18.77M+7,175%$705.22M+25,405%$39.51M-84.3%$245.73M+17,303%$258K-99.9%
-$212.91M-603%$244.07M+2,456%-$222.9M-618%$245.86M+1,050%-$30.28M-84.1%
-$89.27M-12.1%-$66.85M-6.6%-$27.29M+45.4%-$60.58M-27.2%-$79.62M-69.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Kymera Therapeutics generate?
Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
What is Kymera Therapeutics's free cash flow?
After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
Where does Kymera Therapeutics's cash flow data come from?
Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.